INmune Bio (INMB) Expected to Announce Quarterly Earnings on Thursday

Key Points

• INmune Bio is set to announce its Q2 2025 earnings on Thursday, August 7th, with analysts predicting a loss of ($0.37) per share.
• As of the latest trading session, INMB stock is down 15.2% and currently prices at $2.68, significantly lower than its 1-year high of $11.64.
• Analysts have mixed ratings on INmune Bio, with a consensus price target of $18.40, while the stock has been rated as a "Moderate Buy" by MarketBeat.com.

INmune Bio (NASDAQ:INMB - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.

INmune Bio (NASDAQ:INMB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43). The firm had revenue of $0.05 million during the quarter. On average, analysts expect INmune Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

INmune Bio Stock Down 6.2%

INMB stock traded down $0.17 during midday trading on Friday, reaching $2.56. The company had a trading volume of 966,162 shares, compared to its average volume of 2,237,181. The stock has a 50 day moving average price of $4.86 and a 200 day moving average price of $6.89. INmune Bio has a fifty-two week low of $1.89 and a fifty-two week high of $11.64. The firm has a market capitalization of $60.36 million, a PE ratio of -1.33 and a beta of 0.97.

Analysts Set New Price Targets

INMB has been the subject of a number of recent research reports. BTIG Research reiterated a "neutral" rating on shares of INmune Bio in a research report on Tuesday, July 1st. Wall Street Zen downgraded shares of INmune Bio from a "hold" rating to a "sell" rating in a research note on Saturday. Scotiabank reissued a "sector underperform" rating on shares of INmune Bio in a research note on Tuesday, July 1st. Raymond James Financial downgraded shares of INmune Bio from a "moderate buy" rating to a "hold" rating in a research note on Monday, June 30th. Finally, Maxim Group dropped their price target on shares of INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, July 2nd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, INmune Bio has an average rating of "Hold" and an average price target of $18.40.

Hedge Funds Weigh In On INmune Bio

Several hedge funds have recently bought and sold shares of the business. Royal Bank of Canada increased its position in INmune Bio by 44.8% during the first quarter. Royal Bank of Canada now owns 29,863 shares of the company's stock worth $233,000 after buying an additional 9,236 shares during the last quarter. Rhumbline Advisers increased its position in INmune Bio by 14.4% during the first quarter. Rhumbline Advisers now owns 19,153 shares of the company's stock worth $150,000 after buying an additional 2,409 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in INmune Bio during the first quarter worth $142,000. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.